Booth 5951

Maypro announced a new distribution partnership with Xtractiva to bring SaffonX and GarlX to the North American Market. The ingredients will be launched at SupplySide Global.

Xtractiva is a specialist in high-performance and plant-based extracts with its patent-pending Solifuze technology, a clean label process that maximizes purity, potency, dispersibility, and sustained release. Solifuze can improve the solubility of traditionally challenging ingredients, including lipids and hydrophobic or hydrophilic compounds, enabling incorporation into a variety of applications.

SaffonX and GarlX feature absorption optimizing technology that protects actives from stomach pH degradation.

Unlike conventional methods, Solifuze requires minimal excipients or maltodextrin.

SaffonX is a low-dose extract standardized to contain no less than 11% crocins and 0.1% safranal, two bioactive compounds that support mood and emotional well-being.

Garl-X is formulated from aged black garlic that undergoes a natural fermentation process, leading to significant changes in its composition. Garl-X is standardized to contain a minimum of 0.5% S-Allyl Cysteine (SAC), ensuring delivery of a potent and effective form of aged black garlic. It is available in liquid, powder, and granular forms, and is neutral-tasting and can be used in a wide variety of applications and offering benefits for cardiovascular health and immune support.

“SaffonX and Garl-X bridge the gap between tradition and innovation, offering brands clinically backed solutions for key consumer priorities: mental wellness, cognitive clarity, and cardiometabolic vitality,” said Abhijit Natu, vice president of sales and marketing at Maypro. “Maypro has made a name for itself by being among the first to introduce clinically validated ingredients to market. Xtractiva’s portfolio, supported by Solifuze technology, is helping us to continue that tradition.”